Immunome, Inc. (NASDAQ:IMNM) Stock Position Trimmed by Vanguard Group Inc.

Vanguard Group Inc. lessened its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,003,438 shares of the company's stock after selling 128,130 shares during the quarter. Vanguard Group Inc. owned about 3.76% of Immunome worth $31,897,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC grew its position in Immunome by 13.6% during the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock valued at $17,657,000 after acquiring an additional 144,557 shares during the period. Charles Schwab Investment Management Inc. increased its position in Immunome by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company's stock worth $4,856,000 after purchasing an additional 14,775 shares in the last quarter. Magnus Financial Group LLC raised its holdings in Immunome by 107.8% in the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock valued at $569,000 after buying an additional 27,777 shares during the period. Barclays PLC lifted its position in Immunome by 125.9% during the third quarter. Barclays PLC now owns 105,886 shares of the company's stock valued at $1,547,000 after buying an additional 59,016 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Immunome by 137.1% during the third quarter. Wellington Management Group LLP now owns 140,690 shares of the company's stock worth $2,057,000 after buying an additional 81,354 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Trading Up 10.3 %

IMNM stock traded up $0.74 during midday trading on Friday, hitting $7.91. 1,493,908 shares of the company's stock were exchanged, compared to its average volume of 908,202. The firm has a 50 day moving average price of $8.20 and a 200-day moving average price of $10.40. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $17.60. The stock has a market capitalization of $687.78 million, a price-to-earnings ratio of -0.98 and a beta of 2.05.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The company had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, sell-side analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime acquired 7,000 shares of Immunome stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the purchase, the director now directly owns 23,615 shares of the company's stock, valued at $193,879.15. This trade represents a 42.13 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Clay B. Siegall acquired 150,000 shares of the firm's stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares of the company's stock, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 306,400 shares of company stock valued at $2,322,995. Insiders own 8.60% of the company's stock.

Analysts Set New Price Targets

IMNM has been the topic of a number of research reports. Lifesci Capital started coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 target price on the stock. Lake Street Capital began coverage on Immunome in a report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 target price on the stock. Stephens restated an "overweight" rating and issued a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Guggenheim dropped their price objective on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Finally, Wedbush restated an "outperform" rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $25.14.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.